Blue Note logo

×

Creating a New Way Forward

Working closely with leading cancer centers, community oncology clinics, and teams of patients, Blue Note is developing clinically validated prescription digital therapeutics to help reduce anxiety, depression, and other distress related to cancer.

Team

Robert Carbajal

Mobile Engineer: React Native

Sarah Chamberlain

Senior Product Designer

Tim Clark

Director of Engineering

Carlos Craig

Mobile Engineer: React Native

Josh Donahey

Senior Design Quality Assurance Engineer

Alexia Downs

Director, Patient and Business Operations

Geoff Eich

CEO

Jen Feng

Senior Manager, Product Management

Elliott Harris

Patient Service Center Operations Lead

Patrick Kwon

Project Manager, Product Management

My Luu

Director, Human Resources

Michael Malecki, PhD

Head of Access & Reimbursement

Michael McKinley

Head of Product Development

David Rigby

JavaScript Engineer

Jade Rouse

Senior Product Manager

Michelle Rubin-Onur, PhD

Director of Regulatory and Quality

Dianne Shumay, PhD

Head of Behavioral Science

Tyler Smedley

Product Manager

Chloe Taub

Senior Manager, Clinical Psycho-Oncology

Amber Trivedi

Chief Operating Officer

Divyaprabha Ulaganathan

Quality Assurance Engineer

Marlon Velasco

Mobile Game Engineer: Unity

Kevin Wyllie

Design Quality Assurance Engineer

Sean Zion, PhD

Senior Manager, Behavioral Science Research

Abigail Zsarnay

DevOps Build and Release Engineer

Mark Elfers

Business Development Advisor

Lindsay Huffman

Commercialization Advisor

Rick Lit

Regulatory Advisor

Angela Perez

Commercialization Advisor

George Romanko

HR & Talent Advisor

Board of Directors

Gena Cook

Director, Board of Directors

Geoff Eich

Blue Note Therapeutics

Andrew Firlik, MD

Jazz Venture Partners

John Harris

Jazz Venture Partners

Marcus Neubauer, MD

The US Oncology Network

Board of Advisors

Michael Antoni, PhD

Sylvester Comprehensive Cancer Center

Bio  Research

William Breitbart, MD

Memorial Sloan Kettering Cancer Center

Bio  Research

Patricia Ganz, MD

UCLA Jonsson Comprehensive Cancer Center

Bio  Research

Kevin Knopf, MD

UCSF Institute for Health Policy

Bio  Research

Lidia Schapira, MD

Stanford University Medical Center

Bio  Research

Michael Seiden, MD, PhD

Former President, US Oncology Network

Bio

Gregory TenBarge, MHA

Chief Administration Officer, Envision Medical Group

Bio

Betina Yanez, PhD

Northwestern University Feinberg School of Medicine

Bio  Research

Our Pipeline

Blue Note's products will serve all cancer patients, from early stage through survivorship, in both the in-patient and out-patient settings.

Product Candidate Disease Progression Development Proof of Concept Pivotal Trial FDA Review
BNT001 Early - Mid Stage  
BNT200 Acute In-patient    
BNT300 Late Stage      
BNT400 Survivorship      
Product Candidate Disease Progression Status
BNT001 Early - Mid Stage 2
BNT200 Acute In-patient 1
BNT300 Late Stage 0
BNT400 Survivorship 0
Status:
0 = Development
1 = Proof of Concept
2 = Pivotal Trial
3 = FDA Review
 

We Can't Do This Alone

Blue Note Therapeutics is honored to work with the National Comprehensive Cancer Network (NCCN) and other leading cancer care organizations in our quest to help cancer patients live better.